In mid-October, Cardinal Health sent a voluntary medical device product correction letter concerning more than 3.9 million of its syringes because of the issue. As of Oct. 26, more than 16.6 million syringes have been added to the list, according to an FDA database.
The latest notice is classified as a Class I recall, the most serious type; using the product could lead to serious adverse events or death. The first 3.9 million syringes were classified as Class II.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
